A phase Ib/II study of the CD123-targeting antibody-drug conjugate IMGN632 as monotherapy or in combination with venetoclax and/or azacitidine for patients with CD123-positive acute myeloid leukemia.

Autores de IIS La Fe

• Pau Montesinos Fernández

  Autor

Participantes ajenos a IIS La Fe

• Daver, Naval Guastad
• Wang, Eunice S.
• Sweet, Kendra L.
• Erba, Harry Paul
• DeAngelo, Daniel J.
• Sloss, Callum Mortimer
• Wang, Jiuzhou
• Malcolm, Kara E.
• Zweidler-McKay, Patrick A.

Grupos

• Hematología y Hemoterapia

Abstract

Abstract no disponible